Isoproterenol-induced hypertrophy may result in distinct left ventricular changes

Clinical and Experimental Pharmacology and Physiology

Volumn 27, Issue 5-6, 2000, Pages 352-357

  Murad, Neif ^a   Tucci, Paulo J F ^a,b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

Cardiac hypertrophy; Contractile function; Isoproterenol; Left ventricular distensibility; Myocardial mass; Relaxation

Indexed keywords

ISOPRENALINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; DIASTOLE; FIBROSIS; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE HYPERTROPHY; HEART VOLUME; HYPERTROPHY; MALE; NECROSIS; NONHUMAN; RAT; STRESS;

ANIMALS; CARDIOTONIC AGENTS; HEART VENTRICLES; HYPERTROPHY, LEFT VENTRICULAR; ISOPROTERENOL; MALE; RATS; RATS, WISTAR; VENTRICULAR FUNCTION, LEFT;

EID: 0034105298     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1681.2000.03254.x     Document Type: Article

References (26)

1. 1. Rona G, Chappel CI, Balazs T, Gaudry R. An infarct-like myocardial lesion and other toxic manifestations produced by isoproterenol in the rat. Am. Med. Assoc. Arch. Pathol. 1959; 67: 99-111.
2. 2. Taylor PB, Tang Q. Development of isoproterenol-induced cardiac hypertrophy. Can. J. Physiol. Pharmacol. 1984; 62: 384-9.
3. 3. Benjamin IJ, Jalil JE, Tan LB, Cho K, Weber KT, Clark WA. Isoproterenol-induced myocardial fibrosis in relation to myocyte necrosis. Circ. Res. 1989; 65: 657-70.
4. 4. Beznak M. Hemodynamics during the acute phase of myocardial damage caused by isoproterenol. Can. J. Biochem. Physiol. 1962; 40: 25-30.
5. 5. Beznak M, Hacker P. Hemodynamics during the chronic stage of myocardial damage caused by isoproterenol. Can. J. Cardiol. 1964; 42: 269-74.
6. 6. Lin YC. Hemodynamics in the rat with isoproterenol induced cardiac hypertrophy. Res. Commun. Chem. Pathol. Pharmacol. 1973; 6: 213-20.
7. 7. Baldwin KM, Ernst SB, Mullin WJ, Schrader LF, Herrick RE. Exercise capacity and cardiac function of rats with drug-induced cardiac enlargement. J. Appl. Physiol. 1982; 52: 591-5.
8. 8. Tse J, Powell JR, Baste CA, Priest RE, Kuo JF. Isoproterenol-induced cardiac hypertrophy: Modifications in characteristic of β-adrenergic receptor, adenylate cyclase, and ventricular contraction. Endocrinology 1979; 105: 246-55.
9. 9. Hayes JS, Wyss WL, Schenck RS, Cohen ML. Effects of prolonged isoproterenol infusion on cardiac and vascular responses to adrenoceptor agonists. J. Pharmacol. Exp. Ther. 1986; 237: 757-63.
10. 10. Vassalo DV, Vasquez EC, Cabral AM. Contractile performance of papillary muscles of renovascular hypertensive and isoproterenol-pretreated rats. Pharmacol. Res. Commun. 1988; 20: 61-72.
11. 11. Bowling N, Wyss VL, Gengo PJ, Utterback B, Kauffman RF, Hayes IN. Cardiac inotropic responses to calcium and foskolin are not altered by prolonged isoproterenol infusion. Eur. J. Pharmacol. 1990; 187: 155-64.
12. 12. Stein B, Bartel S, Kirchhefer H et al. Relation between contractile function and regulatory cardiac proteins in hypertrophied hearts. Am. J. Physiol. 1996; 270: H2021-8.
13. 13. Taylor PB, White DM. Isoproterenol induced changes in myocardial nucleic acids. Res. Commun. Chem. Pathol. Pharmacol. 1983; 40: 551-4.
14. 14. Tang Q, Taylor PB, Helbing RK. Catecholamine induced cardiac hypertrophy. Can. J. Cardiol. 1987; 3: 311-16.
15. 15. Jalil JE, Doering CW, Janicki JS, Pick R, Shroff SG, Weber KT. Fibrillar collagen and myocardial stiffness in the intact hypertrophied rat left ventricle. Circ. Res. 1989; 64: 1041-50.
16. 16. Cihák R, Kolar F, Pelouch V, Prochazka J, Ostadal B, Widimsky J. Functional changes in the right and left ventricle during development of cardiac hypertrophy and after its regression. Cardiovasc. Res. 1992; 26: 845-50.
17. 17. Arthur GD, Belcastro AN. A calcium stimulated cysteine protease involved in isoproterenol induced cardiac hypertrophy. Mol. Cell Biochem. 1997; 176: 241-8.
18. 18. Tang Q, Taylor PB. Altered contractile function in isoproterenol-induced hypertrophied rat heart. J. Hypertens. 1996; 14: 751-7.
19. 19. Taylor PB, Helbing RK, Rourke S, Churchill D. Effect of catecholamine-induced cardiac hypertrophy on the force-interval relationship. Can. J. Physiol. Pharmacol. 1989; 67: 40-6.
20. 20. Teerlink JR, Pfeffer JM, Pfeffer MA. Progressive ventricular remodeling in response to diffuse isoproterenol-induced myocardial necrosis in rats. Circ. Res. 1994; 75: 105-13.
21. 21. Murad N. Caracterização morfo-funcional da hipertrofia miocárdica induzida em ratos Wistar-EPM pela administração prolongada de isoproterenol, e de sua regressão. PhD Thesis Universidade Federal de São Paulo, São Paulo, Brazil. 1997 (in Portugese).
22. 22. Bing OHL, Brooks WW, Robinson KG et al. The spontaneously hypertensive rat as a model of the transition from compensated left ventricular hypertrophy to failure. J. Mol. Cell Cardiol. 1995; 27: 283-90.
23. 23. Strömer H, Cittadini A, Szymanzka G, Apstein CS, Morgan JP. Validation of different methods to compare isovolumic cardiac function in isolated hearts of varying sizes. Am. J. Physiol. 1997; 272: H501-10.
24. 24. Lewartowski B, Michalowski J, Sedek G. Direct measurement of tension in the intact heart: Diastolic, volume-systolic pressure-tension relation. In: Ciba Foundation Symposia (eds). The Physiological Basis of Starling's Law of the Heart. Associated Scientific Publishers, Amsterdam. 1974; 208-23.
25. 25. MacGregor DC, Covell JW, Mahler F, Dilley RB, Ross JJ. Relations between afterload, stroke volume and descending limb of Starling's curve. Am. J. Physiol. 1974; 227: 884-90.
26. 26. Noble MIM. Engineering and physiological approaches to the study of cardiovascular function: Alternative or complementary? Cardiovasc. Res. 1992; 26: 218-20.